Diligence memo · auto-generated · as of July 2, 2026

Neurona Therapeutics, Inc

Neurona Therapeutics, Inc looks fair against its niche peers and is active on financing cadence.

Diligence furtherNo decisive signal either way from the public record alone — the call needs primary diligence beyond the filings.

Businessfiled

Neurona Therapeutics, Inc operates in Biotechnology, based in SOUTH SAN FRANCISCO.

Sub-sector tags: pharma.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Neurona Therapeutics, Inc has raised $347M in disclosed capital across 6 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).

Largest single filing: $120M on 2024-02-06.

Most recent recorded round closed around 2025-03-28.

Valuation (modeled)modeled

Provath models Neurona Therapeutics, Inc at approximately $875M (range $461M–$1.1B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 0.99× the median modeled value of Series D+ Biotechnology companies in 2025–2027 (33 peers) — value vs value, same stage and era. Within the normal band (99% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 18 months.

Last raise 15 mo ago; this sector typically re-raises about every 14 months.

Raising on or ahead of the sector's normal rhythm.

The last round was 1.2× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 99% of Biotechnology peers (4293 compared).

Modeled value ranks above 88% of those peers.

Closest niche peers: Kriya Therapeutics, Inc., Pathos AI, Inc., Sensei Biotherapeutics, Inc., Odyssey Therapeutics, Inc., Rhodenergy An Environmental Co Corp.

Peoplefiled

17 named people on file across officers, directors and signatories.

Risks & flagsmixed

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.